PPARG and metabolic dysfunction-associated steatohepatitis: This provides the rationale for a PPAR agonist that, in contrast to selective PPAR agonists such as fibrates (PPARα) and thiazolidinediones (PPARγ), has balanced activity on all PPAR isoforms and is thus expected to have direct therapeutic effects on all major nodes of MASH disease biology, from upstream IR, dysregulated lipid and glucose metabolism, inflammation to hepatic fibrogenesis, and thereby to have therapeutic potential for both hepatic and cardiometabolic manifestations of MASH.